Uveal Melanoma

Oncology
13
Pipeline Programs
9
Companies
14
Clinical Trials
5 recruiting
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
3
4
0
3
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
2100%
+ 12 programs with unclassified modality

On Market (1)

Approved therapies currently available

Immunocore
KIMMTRAKApproved
tebentafusp
Immunocore
Bispecific gp100 Peptide-HLA-directed CD3 T Cell Engager [EPC]injection2022

Competitive Landscape

8 companies ranked by most advanced pipeline stage

Immunocore
ImmunocoreOXFORDSHIRE, United Kingdom
5 programs
1
2
1
1
TebentafuspPhase 31 trial
IMCgp100Phase 21 trial
TebentafuspPhase 21 trial
IMCgp100Phase 1/21 trial
TebentafuspN/A1 trial
Active Trials
NCT04960891Available
NCT02570308Completed146Est. Oct 2022
NCT03070392Completed378Est. Sep 2025
+2 more trials
IDEAYA Biosciences
IDEAYA BiosciencesSOUTH SAN FRANCISCO, CA
2 programs
1
1
DarovasertibPhase 3Small Molecule1 trial
DarovasertibPhase 2Small Molecule1 trial
Active Trials
NCT05907954Recruiting160Est. Apr 2030
NCT07015190Recruiting520Est. Mar 2031
Alliance Pharmaceuticals
1 program
1
MelatoninPhase 31 trial
Active Trials
NCT05502900Recruiting100Est. Jan 2031
Aura Biosciences
Aura BiosciencesMA - Boston
2 programs
1
1
AU-011Phase 21 trial
Light-activated AU-011Phase 1/21 trial
Active Trials
NCT03052127CompletedEst. Jan 2021
NCT04417530CompletedEst. Apr 2024
Genentech
GenentechCA - Oceanside
1 program
1
PAC-1Phase 1/21 trial
Active Trials
NCT04589832Terminated6Est. Jun 2022
Novartis
NovartisBASEL, Switzerland
1 program
1
AEB071Phase 11 trial
Active Trials
NCT01430416Completed153Est. May 2019
Bristol Myers Squibb
1 program
1
Isolated hepatic perfusionPhase 11 trial
Active Trials
NCT04463368Completed18Est. Jul 2024
Knight Therapeutics
Knight TherapeuticsQC - Montréal
1 program
Vascular Response to Brachytherapy Using Functional OCTN/A1 trial
Active Trials
NCT01955941Completed49Est. Nov 2021

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
IDEAYA BiosciencesDarovasertib
ImmunocoreTebentafusp
Alliance PharmaceuticalsMelatonin
ImmunocoreTebentafusp
IDEAYA BiosciencesDarovasertib
Aura BiosciencesAU-011
ImmunocoreIMCgp100
GenentechPAC-1
Aura BiosciencesLight-activated AU-011
ImmunocoreIMCgp100
Bristol Myers SquibbIsolated hepatic perfusion
NovartisAEB071
Knight TherapeuticsVascular Response to Brachytherapy Using Functional OCT

Clinical Trials (14)

Total enrollment: 1,864 patients across 14 trials

NCT07015190IDEAYA BiosciencesDarovasertib

Neoadjuvant Darovasertib in Primary Uveal Melanoma

Start: Jan 2026Est. completion: Mar 2031520 patients
Phase 3Recruiting
NCT06246149ImmunocoreTebentafusp

Adjuvant Tebentafusp in High Risk Ocular Melanoma

Start: Nov 2024Est. completion: Nov 2032290 patients
Phase 3Recruiting
NCT05502900Alliance PharmaceuticalsMelatonin

Adjuvant Melatonin for Uveal Melanoma

Start: Oct 2022Est. completion: Jan 2031100 patients
Phase 3Recruiting
NCT06070012ImmunocoreTebentafusp

Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma

Start: Aug 2025Est. completion: Sep 203044 patients
Phase 2Recruiting
NCT05907954IDEAYA BiosciencesDarovasertib

(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma

Start: Jul 2023Est. completion: Apr 2030160 patients
Phase 2Recruiting
NCT04417530Aura BiosciencesAU-011

Phase 2 Trial to Evaluate Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma

Start: Aug 2020Est. completion: Apr 2024
Phase 2Completed
NCT03070392ImmunocoreIMCgp100

Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma

Start: Oct 2017Est. completion: Sep 2025378 patients
Phase 2Completed
NCT04589832GenentechPAC-1

Study of PAC-1 and Entrectinib for Patients With Metastatic Uveal Melanoma

Start: Jan 2021Est. completion: Jun 20226 patients
Phase 1/2Terminated
NCT03052127Aura BiosciencesLight-activated AU-011

Study in Subjects With Small Primary Choroidal Melanoma

Start: Feb 2017Est. completion: Jan 2021
Phase 1/2Completed
NCT02570308ImmunocoreIMCgp100

A Study of the Intra-Patient Escalation Dosing Regimen With IMCgp100 in Patients With Advanced Uveal Melanoma

Start: Feb 2016Est. completion: Oct 2022146 patients
Phase 1/2Completed
NCT04463368Bristol Myers SquibbIsolated hepatic perfusion

Isolated Hepatic Perfusion in Combination With Ipilimumab and Nivolumab in Patients With Uveal Melanoma Metastases

Start: Mar 2021Est. completion: Jul 202418 patients
Phase 1Completed
NCT01430416NovartisAEB071

Safety and Efficacy of AEB071 in Metastatic Uveal Melanoma Patients

Start: Dec 2011Est. completion: May 2019153 patients
Phase 1Completed
NCT04960891ImmunocoreTebentafusp

A Cohort IND Expanded Access Program for Supporting Patient Access to Tebentafusp

N/AAvailable
NCT01955941Knight TherapeuticsVascular Response to Brachytherapy Using Functional OCT

Vascular Response to Brachytherapy Using Functional OCT

Start: Oct 2013Est. completion: Nov 202149 patients
N/ACompleted

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
2h ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
2h ago

Office Administrator

SystImmune
2h ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
3h ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
3h ago

Working Student Active Sourcing Support (m/f/d)

Mindpeak
Hamburg
3h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 late-stage (Phase 3) programs — potential near-term approvals
5 actively recruiting trials targeting 1,864 patients
9 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)